Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions
NCT05347576Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Apr 2022
- Primary completion
- May 2022
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-393 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve from dosing to time t at 48 hours and Maximum Plasma Concentration at 48 hours. Started Apr 2022; status: completed.
02
Drugs
CKD-393
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05347576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05347576.